A Novel PEtOx-Based Nanogel Targeting Prostate Cancer Cells for Drug Delivery

Area of Science:

• Materials Science
• Polymer Chemistry
• Nanotechnology
• Biomedical Engineering

Background:

• Targeted drug delivery systems are crucial for improving cancer treatment efficacy and reducing side effects.
• Prostate cancer requires innovative therapeutic strategies, including advanced drug delivery platforms.
• Nanogels offer versatile properties for encapsulating and delivering therapeutic agents.

Purpose of the Study:

• To synthesize and characterize a novel nanogel for targeted drug delivery in prostate cancer.
• To evaluate the nanogel's biocompatibility, stability, and drug-releasing capabilities.
• To assess the targeting efficiency and cellular uptake of the peptide-conjugated nanogel in tumor cells.

Main Methods:

• Synthesis of poly(2-ethyl-2-oxazoline) (PEtOx) nanogels using living/cationic ring-opening polymerization (CROP) and click chemistry.
• Characterization of nanogel properties including size, morphology, and stability using techniques like DLS, SEM, TEM, ¹H-NMR, and FT-IR.
• In vitro evaluation of nanogel cytotoxicity using MTT assays and assessment of targeting efficiency via cellular uptake studies.

Main Results:

• Uniform, spherical nanogels with controllable sizes (100-296 nm) and good stability in physiological conditions were successfully synthesized.
• Nanogels demonstrated dose-dependent cytotoxicity and enhanced efficacy when loaded with drugs, showing higher cytotoxicity against cancer cells.
• Peptide 563 conjugation significantly increased nanogel intracellular uptake by tumor cells (60-fold higher compared to non-conjugated nanogels).

Conclusions:

• The developed nanogel system is a promising platform for targeted drug delivery in cancer therapy, particularly for prostate cancer.
• The nanogel's ease of synthesis, tunable functionality, non-toxicity, and enhanced tumor cell uptake highlight its therapeutic potential.
• Further development could lead to advanced, effective treatments with improved patient outcomes in oncology.